Navigation Links
YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
Date:12/12/2008

MISSISSAUGA, Canada, Dec. 12 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that its majority-owned subsidiary CIMYM BioSciences Inc. received a milestone payment from its licensee Innogene Kalbiotech Ltd (IGK) in recognition of the recent marketing approval of nimotuzumab in the Philippines and Indonesia. IGK is the biotech subsidiary of P.T Kalbe Farma Tbk (Jakarta, Indonesia), one of the largest pharmaceutical companies in the region with more than 8,100 employees and annual revenues exceeding US$300 million.

"With the addition of the Philippines and Indonesia, nimotuzumab has now received marketing approval in twelve countries. Demand for novel medicines is growing rapidly in the emerging markets of the world and nimotuzumab is well positioned to become a key cancer therapeutic in these territories due to its unique safety profile compared with the other EGFR-targeting drugs," said David Allan, Chairman and CEO of YM BioSciences. "Highlighting this competitive advantage, reports have increased in frequency describing toxicities associated with the combination of the other EGFR drugs and radiation. In addition to Grade III/IV rash, Grade IV radiation dermatitis, another serious and debilitating toxicity, has recently been reported affecting approximately 28% of patients treated with a currently marketed EGFR-targeting antibody together with radiation while absent in patients treated with radiation alone."

In none of the clinical trials of nimotuzumab to date, to YM's knowledge, have any of the patients developed Grade III/IV acneiform rash, also a severe and dose-limiting side-effect observed in all of the other antibodies and with small molecules targeting the EGF tyrosine kinase signaling pathway. Unrelated to the rash, Grade III/IV radiation dermatitis is a severe toxici
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
2. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
3. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
4. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
5. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
6. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
7. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
8. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
9. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
10. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014  Air Products (NYSE: ... medical oxygen is vital to any healthcare facility. This ... not only improve the efficiency of its oxygen supply ... highlight these systems—including systems for emergency oxygen supply ... August 4-5 at the 51 st ASHE ...
(Date:7/28/2014)... 28, 2014 Southern Research Institute today ... President and CEO of Southern Research Institute, has ... (CRS) for the 2014-2015 term.  The inauguration took ... 12 in Chicago with ... The Controlled Release Society is an international, ...
(Date:7/28/2014)... WELLINGTON, New Zealand , July 28, 2014 ... Institute in Sweden has ... across multiple vendor platforms and has associated volumetrically ... Published in Cancer Epidemiology, Biomarkers & Prevention ... volumetric mammographic density: a tool for widespread breast ...
Breaking Medicine Technology:Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 2Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4
... Cardinal Health today announced its board of directors has approved a ... will join the company,s board of directors. At ... per share, payable on Oct. 15 to shareholders of record on ... for Cardinal Health. The board of directors also ...
... The National Pharmaceutical Council (NPC) today welcomed global specialty ... Jeffrey M. Jonas, senior vice president, specialty pharma R&D, ... of directors. "The last few years ... has left many important questions unresolved.  For the pharmaceutical ...
Cached Medicine Technology:Cardinal Health Board of Directors Approves Cash Dividend, Elects David P. King as Director 2Cardinal Health Board of Directors Approves Cash Dividend, Elects David P. King as Director 3National Pharmaceutical Council Welcomes Shire as Its Newest Member 2
(Date:7/28/2014)... Quincy Bioscience, makers of the nation’s leading memory ... release of the fourth edition of The Brain Health ... , The Brain Health Guide is a unique resource ... to improve memory and promote optimal aging. Rather than ... Guide provides ways to help minimize common memory lapses ...
(Date:7/28/2014)... surgical procedure to treat severe chronic migraine headaches led ... the time in patients treated at Massachusetts General Hospital ... and Reconstructive Surgery report that more than half of ... of whom had headaches associated with compression of craniofacial ... The team,s paper has received advance online publication ...
(Date:7/28/2014)... Cape Regional Medical Center, is ... technology solution in an effort to streamline its ... with their New Jersey health information exchange (NJSHINE). ... in New Jersey, serves the local population and ... of inpatient and outpatient services. With a strong ...
(Date:7/28/2014)... July 28, 2014 (HealthDay News) -- Endurance runners are ... an undetected heart condition, according to a new study. ... participating in events in warm climates are actually 10 ... stroke. Yet, the less common sudden death of a ... problems, such as an irregular heartbeat, often gets a ...
(Date:7/28/2014)... The Oakwood Foundation celebrated a major ... and Associates, PC that will benefit each community we ... , The HBWS group is among the Foundation’s ... million in donations. Through their latest gift, they will ... Women’s Healthcare Classic for the next 6 years; provide ...
Breaking Medicine News(10 mins):Health News:Quincy Bioscience Launches the Fourth Edition of The Brain Health Guide 2Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2
... cases in China and Indonesia, the World Health Organization (WHO) ... with the H5N1 // avian influenza virus that has resulted ... birds. ,More than half the people infected – ... the announcement from Beijing officials November 16 that its Centre ...
... tourism destination was the highlight of presentations made at ... Minister for Tourism Renuka Chowdhury, who // inaugurated the ... "Not only is India known for its hospitality, but ... Indians know how to do the best"., ,Chowdhury ...
... cancer is being used in a leading private hospital ... using new laser technology. This will pave way for ... said that with its new KTP laser, surgery would ... within 24 hours. Earlier, patients had to stay at ...
... III study involving the use of Actemra in the ... superior to conventional treatment modality that uses disease modifying ... has also been found to provide symptomatic relief and ... a debilitating autoimmune disease in which the lining of ...
... converted human embryonic stem cells into cartilage cells, ... be grown for transplantation for a number of ... new cartilage for people having hip replacements, and ... ,The research, to be published in the journal ...
... developing tests that can identify the beginnings of Alzheimers years ... ,The researchers, who presented their results on 14 // ... in Washington DC, say the tests allowed them to single ... those results are repeated using larger study groups, doctors could ...
Cached Medicine News:Health News:Novel Actemra monotherapy in treating patients with early aggressive rheumatoid arthritis 2Health News:Another Potential Of Stem Cells Discovered: Used For Growing Cartilage 2Health News:Diagnosis of Alzheimer's years before clinical signs emerge 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: